Scopus Biopharma Probability of Future OTC Stock Price Finishing Under 0.1
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus |
Scopus Biopharma Target Price Odds to finish below 0.1
The tendency of Scopus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 0.10 | 90 days | 0.10 | about 18.97 |
Based on a normal probability distribution, the odds of Scopus Biopharma to move below current price in 90 days from now is about 18.97 (This Scopus Biopharma probability density function shows the probability of Scopus OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Scopus Biopharma has a beta of -0.52. This usually implies as returns on the benchmark increase, returns on holding Scopus Biopharma are expected to decrease at a much lower rate. During a bear market, however, Scopus Biopharma is likely to outperform the market. Additionally Scopus Biopharma has an alpha of 0.3862, implying that it can generate a 0.39 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Scopus Biopharma Price Density |
| Price |
Predictive Modules for Scopus Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Scopus Biopharma. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Scopus Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Scopus Biopharma is not an exception. The market had few large corrections towards the Scopus Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Scopus Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Scopus Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.39 | |
β | Beta against Dow Jones | -0.52 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | 0.01 |
Scopus Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Scopus Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Scopus Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Scopus Biopharma is not yet fully synchronised with the market data | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
Scopus Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Scopus OTC Stock often depends not only on the future outlook of the current and potential Scopus Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Scopus Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.4 M | |
| Cash And Short Term Investments | 7.9 M |
Scopus Biopharma Technical Analysis
Scopus Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Scopus OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Scopus Biopharma. In general, you should focus on analyzing Scopus OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Scopus Biopharma Predictive Forecast Models
Scopus Biopharma's time-series forecasting models is one of many Scopus Biopharma's otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Scopus Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Scopus Biopharma
Checking the ongoing alerts about Scopus Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Scopus Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Scopus Biopharma is not yet fully synchronised with the market data | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |